Author

Silvia Urbina

Institution: Altimmune (United States)

Observed institution: Altimmune (United States)

ORCID: 0000-0001-5893-4621

Observed ORCID: 0000-0001-5893-4621

OpenAlex ID: A5068590052

Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study

2025 · Mazen Noureddin, Stephen A Harrison, et al. · The Lancet · 59

Adipose tissue measurement in clinical research for obesity, type 2 diabetes and NAFLD/NASH

2022 · Adrian Vilalta, Julio A. Gutiérrez, et al. · Endocrinology Diabetes & Metabolism · 34

A Randomized Crossover Trial of Mixed Meal Tolerance Test Response in People with Type 1 Diabetes on Insulin Pump Therapy and YG1699 or Dapagliflozin

2024 · Pablo Lapuerta, Silvia Urbina, et al. · Clinical Pharmacology & Therapeutics · 1

Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 48-week results from a multicentre, randomised, double-blind, phase 2b study

2026 · Mazen Noureddin, Naim Alkhouri, et al. · The Lancet. Gastroenterology & hepatology

Works count: 4

Citation count: 94

H-index: 2

I10-index: 2